Utility of Routine Follow-Up Defibrillator Threshold Testing in Congenital Heart Disease and Pediatric Populations

Authors: ELIZABETH A. STEPHENSON1; FRANK CECCHIN1; EDWARD P. WALSH1; CHARLES I. BERUL1

Source: Journal of Cardiovascular Electrophysiology, Volume 16, Number 1, January 2005 , pp. 69-73(5)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

DFT Follow-Up in Congenital Heart Disease and Pediatric Populations.

Introduction: Recent studies have suggested that routine defibrillation threshold (DFT) testing of implantable cardioverter defibrillators (ICDs) in adults may not be necessary. The congenital heart disease and pediatric populations are a unique group of ICD recipients having a higher incidence of lead failure. We investigated the utility of follow-up DFT testing in this population.

Methods and Results: The records of 155 ICD recipients at one center were retrospectively reviewed, and patients having one or more follow-up DFT tests were analyzed. The patients were divided into two groups. The “routine” group consisted of 58 follow-up DFT procedures in 46 patients, without known changes in ICD parameters. The “prompted” group consisted of 21 follow-up DFT procedures in 18 patients, motivated by clinical concerns about changes in ICD lead status. Of 58 “routine” DFTs performed at a mean postimplant duration of 32 ± 23 months (range 2–78), 7 (12%) had reprogramming, and 1 required a hardware change as a result of the testing. Of the 21 “prompted” DFTs performed, 7 required device reprogramming, and 3 required hardware upgrade. Overall, 19 (24%) of 79 procedures detected clinically significant changes, requiring reprogramming or ICD system revision. No complications were seen from follow-up DFT testing.

Conclusion: A high rate of abnormalities was found at follow-up DFT testing in this population, especially in the group of patients with clinically prompted testing. Clinically indicated DFT testing, as expected, has a high yield of important information on device function in congenital heart disease and pediatric populations.

(J Cardiovasc Electrophysiol, Vol. 16, pp. 69-73, January 2005)

Keywords: implantable defibrillator; pediatric devices; congenital heart disease

Document Type: Research article

DOI: 10.1046/j.1540-8167.2005.04528.x

Affiliations: 1: Department of Cardiology, Children's Hospital, Boston, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A